For example, combined treatment of Polyoxotungstate-1 (POM1; CD39 inhibitor) and anti-PD1 and CTLA-4 antibodies in B16-F10 (melanoma cells) transplanted mice model showed a remarkable reduction in tumor burden and increase in the survival of tumor-bearing mice [298]. Here, ENTPD1 is linked to neoplasm.